Table of Contents
Innovative Drugs to Launch in the Next 3 Years, Impacting the Insulin and Non-insulin Markets
This research service focuses on insulin and non-insulin therapeutics for the treatment of type 1 and 2 diabetes in Latin America. The insulin and non-insulin markets will experience major changes within the next three years, due to the discovery of new drugs. Focus is currently placed on the development of molecules that can help with patients’ adherence to treatment by offering one weekly drug dose for managing the chronic disease. This deliverable includes information regarding market background, dynamics, challenges, trends, and access. The base year is 2013. Also, provided are a detailed analysis of products on the market and in development within Latin America, as well as clinical trial details and projected drugs launch timelines.
Methodology and Scope
•This research service focuses on therapeutics for the treatment of type 1 and 2 diabetes.
•This deliverable includes information regarding the challenges and trends of these markets, detailed analysis of products on the Latin American market, as well as clinical trial projected launch timelines.
•The information contained in this research service was derived from interviews with key opinion leaders of the industry and from published sources including the following: disease organization Web sites; public health organization Web sites; company publications and press releases; government public sources; and published articles in scientific journals.
•The insulin and non-insulin markets will experience major changes within the next three years, due to the discovery of new drugs.
oThe focus is placed on the development of molecules that can help with patients’ adherence to treatment by offering one weekly drug dose for the management of the chronic disease.
•As patients do not show symptoms during the early and middle stages of the disease, the recurrent use of drugs for the management of diabetes is limited, hence reducing their permanence in the treatment.
•The target is to reach the X% of diagnosed patients in Latin America (LATAM) that are not adequately completing their treatment.
•Novo Nordisk’s semaglutide drug constitutes a practical consequence of the above factors. If introduced into the market, it will offer a once-a-week option for the treatment of type 2 diabetes.
oThe drug is in the late stage of development and is currently in ongoing clinical trials. It is expected to reach the LATAM market by 2016, impacting in the non-insulin therapeutics market.
•Patients with metabolic syndrome usually need to separately administer drugs for diabetes, arterial hypertension, and hyperlipidemia. Pharmaceutical companies are seeking to supply current and future patients with a single tablet that contains adequate doses for the drugs required for the treatment of each of those diseases in order to improve treatment therapy.
oThat is the case of the GSK* glimepiride/atorvastatin fixed dose combination tablet, which just completed Phase III clinical trials.
•Novo Nordisk is developing degludec, a new type of basal insulin that is expected to be launched in the LATAM market by 2014. Clinical trials have demonstrated the superiority of the product versus Sanofi’s glargine. This new medication is expected to become the leader of the basal insulin segment.
•Several investigations are being conducted for the development of an oral administration insulin around the globe. In Mexico, the Conacyt Investigation Public Centre, together with the University of Sonora, are working on the development of a capsule that avoids insulin gastrointestinal degrading.
•Human and animal insulin biosimilars are available in the LATAM market, offering low cost alternatives. Still, these kinds of insulin are rarely recommended by physicians due to their reduced effectiveness and security.
•Diabetes is a chronic progressive disease of the endocrine system in which, during the metabolism of carbohydrates, the body is unable to maintain and control the blood glucose level.
•Chronic exposure to elevated glucose can eventually lead to microvascular complications, such as peripheral neuropathy (nerve damage), nephropathy (kidney disease), retinopathy (vision loss), macrovascular complications (cardiovascular disease), and death.
•Type 2 diabetes usually presents in adolescent and adult patients, as opposed to type 1 diabetes that is a juvenile-onset chronic autoimmune disease. Type 2 diabetes is strongly associated with obesity, which is the main risk factor.
oOther risk factors include age, family history, inactivity, history of gestational diabetes, and race/ethnicity.
•The goal of diabetes treatment is to maintain glucose levels that are as close to normal as possible without risking hypoglycemia as a way to prevent or delay complications and death.
Get Industry Insights. Simply.
Talk to Ahmad
+1 718 618 4302
The global insulin market is expected to reach USD 42 billion by 2020, growing at a CAGR of XX%. Insulin is a peptide hormone secreted by the beta cells in the pancreas. Insulin maintains the metabolism ...
China’s demand for Diabetes Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth ...
China’s demand for Insulin has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which ...